Some fusion biopharmaceutical proteins are available in the market and represent a substantial part of the drug market, such as Ontak®(IL-2 and denileukin diftitox for cutaneous T-cell lymphoma) and Idelvion® (Factor IX and albumin for hemophilia B). This evidence concerns the gene F9 and primary cutaneous T-cell non-Hodgkin lymphoma.